{"abstract":"The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled \"Patient-Focused Drug Development on Opioid Use Disorder.\" The purpose of the public meeting is to obtain patients' perspectives on the impacts of and treatment approaches for opioid use disorder (OUD). This meeting is a part of FDA's ongoing work aimed at reducing the impact of opioid abuse and addiction.","action":"Notice of public meeting; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/03/14/2018-05119.html","cfr_references":[],"citation":"83 FR 11208","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"The public meeting will be held on April 17, 2018, from 10 a.m. to 4 p.m. Submit either electronic or written comments on this public meeting by June 18, 2018. See the SUPPLEMENTARY INFORMATION section for registration date and information.","disposition_notes":null,"docket_ids":["Docket No. FDA-2018-N-0987"],"dockets":[],"document_number":"2018-05119","effective_on":null,"end_page":11210,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/03/14/2018-05119.xml","html_url":"https://www.federalregister.gov/documents/2018/03/14/2018-05119/patient-focused-drug-development-on-opioid-use-disorder-public-meeting-request-for-comments","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-05119?publication_date=2018-03-14","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-03-14/2018-05119/mods.xml","not_received_for_publication":null,"page_length":3,"page_views":{"count":895,"last_updated":"2026-09-23 04:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-03-14/pdf/2018-05119.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-05119.pdf?1520945126","publication_date":"2018-03-14","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/03/14/2018-05119.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2018-N-0987","supporting_documents_count":0,"docket_id":"FDA-2018-N-0987","regulation_id_number":null,"title":"Patient-Focused Drug Development on Opioid Use Disorder; Public Meeting; Request for Comments","checked_regulationsdotgov_at":"2018-07-12T09:00:15Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":11208,"subtype":null,"title":"Patient-Focused Drug Development on Opioid Use Disorder; Public Meeting; Request for Comments","toc_doc":"Patient-Focused Drug Development on Opioid Use Disorder","toc_subject":"Meetings:","topics":[],"type":"Notice","volume":83}